Table 1.
The patients’ characteristics
| Characteristic | N (%) patients or median (range) |
|---|---|
| Total enrolled | 38 |
| Sex (M/F) | 31(82)/7(18) |
| Age, years | 55 (36–71) |
| Interval, months: | |
| first diagnosis to metastasis | 5 (0–264) |
| metastatic disease to metastasectomy | 9 (5–56) |
| Haemoglobin, g/dL, at registration | 12.3 (8.8–15.2) |
| Calcium, g/dL, at registration | 9.5 (1.4–10.8) |
| Systemic therapy before surgery, months | 5 (3–15) |
| Pathology at diagnosis | |
| Conventional | 33 (87) |
| Mixed | 5 (13) |
| Sites of first metastasis | |
| Lung/lung only | 21(55)/18(47) |
| Lymph node/lymph node only | 12(32)/5 (13) |
| Renal bed/renal bed only | 6(16)/4 (10.5) |
| Bone/bone only | 4 (10.5)/3 (8) |
| Other | 4 (10.5) |
| Previous nephrectomy/embolization | 37 (97)/1 (3) |
| Type of previous immunotherapy for metastatic disease | |
| IL-2-containing regimen | 17 (45) |
| Non-IL2-containing regimen | 21 (55) |
| Response to previous immunotherapy | |
| CR or PR | 8 (21) |
| Stable response | 30 (79) |